PriceTargets.com logo

Olema Pharmaceuticals - OLMA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $44.89
  • Forecasted Upside: 203.69%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$14.78 As of 03/19/2026 10:55 AM ET
▲ +0.221 (1.52%)

This chart shows the closing price for OLMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Olema Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OLMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OLMA

Analyst Price Target is $44.89
▲ +203.69% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $44.89, with a high forecast of $62.00 and a low forecast of $27.00. The average price target represents a 203.69% upside from the last price of $14.78.

This chart shows the closing price for OLMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Olema Pharmaceuticals. This rating has held steady since July 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/19/2026Jefferies Financial GroupInitiated CoverageBuy
3/18/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$55.00 ➝ $58.00
3/18/2026The Goldman Sachs GroupLower TargetBuy ➝ Buy$38.00 ➝ $27.00
3/17/2026CitigroupBoost TargetBuy ➝ Buy$60.00 ➝ $62.00
3/17/2026GuggenheimLower TargetBuy ➝ Buy$40.00 ➝ $38.00
3/9/2026TD CowenReiterated RatingBuy ➝ Buy
3/9/2026OppenheimerReiterated RatingOutperform ➝ Outperform
3/9/2026HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $38.00
2/11/2026Stifel NicolausInitiated CoverageBuy$48.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/7/2026UBS GroupInitiated CoverageBuy ➝ Buy$45.00
1/7/2026UBS GroupInitiated CoverageBuy$45.00
1/7/2026Piper SandlerInitiated CoverageOverweight$40.00
12/12/2025CitigroupBoost TargetBuy ➝ Buy$21.00 ➝ $60.00
12/11/2025OppenheimerBoost TargetOutperform ➝ Outperform$45.00 ➝ $48.00
12/11/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$26.00 ➝ $38.00
12/11/2025HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $45.00
11/21/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$18.00 ➝ $26.00
11/18/2025OppenheimerBoost TargetOutperform ➝ Outperform$22.00 ➝ $45.00
11/18/2025HC WainwrightBoost TargetBuy ➝ Buy$28.00 ➝ $36.00
11/18/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$29.00 ➝ $32.00
10/20/2025UBS GroupReiterated RatingBuy ➝ Buy
10/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025GuggenheimInitiated CoverageBuy$20.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/9/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/3/2025OppenheimerReiterated RatingOutperform ➝ Outperform$22.00
8/14/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$28.00 ➝ $29.00
8/12/2025CitigroupBoost TargetBuy ➝ Buy$20.00 ➝ $21.00
8/11/2025Zacks ResearchUpgradeStrong Sell
5/14/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$20.00 ➝ $18.00
5/14/2025OppenheimerLower TargetOutperform ➝ Outperform$25.00 ➝ $22.00
4/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/28/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$30.00 ➝ $28.00
3/19/2025OppenheimerReiterated RatingOutperform ➝ Outperform$30.00 ➝ $25.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
12/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/8/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$33.00 ➝ $31.00
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/7/2024OppenheimerReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
5/9/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $28.00
4/2/2024The Goldman Sachs GroupInitiated CoverageBuy$24.00
2/22/2024Capital One FinancialReiterated RatingOverweight
1/30/2024CitigroupInitiated CoverageBuy$20.00
10/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
9/15/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$16.00 ➝ $19.00
9/6/2023OppenheimerReiterated RatingOutperform ➝ Outperform$21.00
9/5/2023HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $28.00
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$14.00 ➝ $16.00
8/9/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $22.00
8/9/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$16.00 ➝ $18.00
7/20/2023OppenheimerInitiated CoverageOutperform$21.00
5/12/2023Capital One FinancialBoost Target$16.00 ➝ $20.00
5/10/2023HC WainwrightLower Target$15.00 ➝ $14.00
5/5/2023Capital One FinancialInitiated CoverageOverweight$16.00
4/26/2023Lifesci CapitalReiterated RatingOutperform
3/10/2023Credit Suisse GroupLower TargetOutperform$12.00 ➝ $11.00
3/10/2023HC WainwrightBoost TargetBuy$12.00 ➝ $15.00
2/22/2023Credit Suisse GroupInitiated CoverageOutperform$12.00
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$16.00
6/9/2022HC WainwrightUpgradeNeutral ➝ Buy$12.00
2/28/2022HC WainwrightInitiated CoverageNeutral
6/21/2021Lifesci CapitalReiterated RatingOutperform
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 4 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
11/19/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/19/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 12 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 12 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Olema Pharmaceuticals logo
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $14.78
Low: $14.36
High: $14.97

50 Day Range

MA: $23.56
Low: $14.60
High: $29.19

52 Week Range

Now: $14.78
Low: $2.86
High: $36.26

Volume

131,964 shs

Average Volume

1,599,494 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Olema Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Olema Pharmaceuticals in the last year: Citigroup Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings, Inc., Piper Sandler, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for OLMA.

What is the current price target for Olema Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Olema Pharmaceuticals in the last year. Their average twelve-month price target is $44.89, suggesting a possible upside of 207.5%. Citigroup Inc. has the highest price target set, predicting OLMA will reach $62.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $27.00 for Olema Pharmaceuticals in the next year.
View the latest price targets for OLMA.

What is the current consensus analyst rating for Olema Pharmaceuticals?

Olema Pharmaceuticals currently has 1 sell rating, 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OLMA.

What other companies compete with Olema Pharmaceuticals?

Other companies that are similar to Olema Pharmaceuticals include Crinetics Pharmaceuticals, Indivior, Centessa Pharmaceuticals, Structure Therapeutics and Amneal Pharmaceuticals. Learn More about companies similar to Olema Pharmaceuticals.

How do I contact Olema Pharmaceuticals' investor relations team?

Olema Pharmaceuticals' physical mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The company's listed phone number is 650-243-5555 and its investor relations email address is [email protected]. The official website for Olema Pharmaceuticals is www.olema.com. Learn More about contacing Olema Pharmaceuticals investor relations.